stockportfolio.pro
United Therapeutics Corporation (UTHR)
Healthcare · Drug Manufacturers - Specialty & Generic · NasdaqGS
United Therapeutics Corporation revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.60B | $1.73B | $1.63B | $1.45B | $1.48B | $1.69B | $1.94B | $2.33B | $2.88B | $3.18B |
| Gross profit | $1.53B | $1.62B | $1.43B | $1.33B | $1.38B | $1.56B | $1.78B | $2.07B | $2.57B | $2.80B |
| Net income | $713.70M | $417.90M | $589.20M | $-104.50M | $0 | $475.80M | $727.30M | $984.80M | $1.20B | $1.33B |
| Net margin | 44.6% | 24.2% | 36.2% | -7.2% | 0.0% | 28.2% | 37.6% | 42.3% | 41.5% | 41.9% |
Source: United Therapeutics Corporation SEC filings (10-K). 18 years of history available in the interactive view.
What growth is priced into UTHR stock?
At today's market cap of $23.00B, United Therapeutics Corporation is priced for free-cash-flow growth of about 9.1% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.04B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 8.4%/yr over the last five fiscal years and revenue 16.5%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 18 years of United Therapeutics Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track UTHR in your portfolio →
United Therapeutics Corporation financial history by metric
About United Therapeutics Corporation
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
United Therapeutics Corporation — frequently asked questions
What is United Therapeutics Corporation's revenue?
United Therapeutics Corporation (UTHR) reported revenue of $3.18B for fiscal year 2025, up 10.6% from the prior year, according to its SEC filings.
Is United Therapeutics Corporation profitable?
Yes. UTHR earned net income of $1.33B in fiscal 2025, a net margin of 41.9%.
What is UTHR's P/E ratio?
United Therapeutics Corporation trades at a price-to-earnings ratio of about 20.0 based on the latest data in our nightly-refreshed cache.
How fast is United Therapeutics Corporation growing?
UTHR's revenue grew at roughly 16.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does United Therapeutics Corporation have?
As of fiscal year 2025, UTHR carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is United Therapeutics Corporation's gross margin?
UTHR's gross margin was 87.9% in fiscal 2025 — gross profit of $2.80B on revenue of $3.18B.
What is United Therapeutics Corporation's market cap?
United Therapeutics Corporation (UTHR) has a market capitalization of about $23.00B, based on the latest data in our nightly-refreshed cache.
When does United Therapeutics Corporation's fiscal year end?
UTHR's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into UTHR stock?
At today's market cap of $23.00B, United Therapeutics Corporation is priced for free-cash-flow growth of about 9.1% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.04B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 8.4%/yr over the last five fiscal years and revenue 16.5%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from United Therapeutics Corporation's official SEC filings (10-K and 10-Q), covering 18 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.